QGEN - QIAGEN partners with Mirati Therapeutics to develop companion diagnostic

QIAGEN N.V. (QGEN) announces a global collaboration with Mirati Therapeutics (MRTX) to continue developing a tissue-based KRAS companion diagnostic to identify certain patients with cancers that have a KRASG12C mutation.The diagnostic aims to identify patients with the condition who may benefit from treatment with adagrasib, Mirati’s investigational, highly selective and potent oral small molecule inhibitor of KRASG12C.The agreement initially focuses on a companion diagnostic test for non-small cell lung cancer ((NSCLC)), and allows for further development of tests for other Mirati oncology programs.QIAGEN and Mirati have previously partnered for the development of a companion diagnostic.QIAGEN and Inovio Pharmaceuticals (INO) had announced an extension of their partnership to develop liquid biopsy-based companion diagnostic products to complement Inovio’s therapies, in February.

For further details see:

QIAGEN partners with Mirati Therapeutics to develop companion diagnostic